Table 1. Table demonstrating proportion of patients (%) treated with isotonic or hypotonic riboflavin whose LogMAR UCVA and BSCVA either improved, deteriorated, or remained stable at 9 and 12 months from baseline.
|
Isotonic |
Hypotonic |
|||||||
|---|---|---|---|---|---|---|---|---|
|
9 Months |
12 Months |
9 Months |
12 Months |
|||||
| UCVA | BSCVA | UCVA | BSCVA | UCVA | BSCVA | UCVA | BSCVA | |
| Improved by 2 lines or more | 39.0 | 52.9 | 41.8 | 29.7 | 0 | 33.3 | 25.0 | 25.0 |
| Deteriorated by 2 lines or more | 24.4 | 14.7 | 13.4 | 14.9 | 33.3 | 0.0 | 8.3 | 0.0 |
| Remained stable (within 2 lines of baseline) | 36.6 | 32.4 | 44.8 | 55.4 | 66.7 | 66.7 | 66.7 | 75.0 |